Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 11, 2023, titled "Zydus andDaewoong Pharmaceutical announce exclusive licensing agreement for development andcommercialization of Leuprolide Long-Acting Injectable in the U.S.".
Press Release Dec 11 2023
Filed with NSE · · 3 pages · English
Summary by 6ix AI
This agreement includes milestone payments and profit sharing based on future sales. The partnership aims to enhance patient access to affordable therapies in the healthcare market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 06 2023
- Press Release Dec 01 2023
- Press Release Nov 10 2023
- Press Release Nov 07 2023
- Press Release Nov 06 2023
Later from Zydus Lifesciences
- Press Release Dec 14 2023
- Press Release Dec 15 2023
- Press Release Dec 16 2023
- Press Release Dec 22 2023
- Press Release Jan 17 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences